Logo
x

Search

Subscribe Now

diffuse large b-cell lymphoma

Antengene's Receives NMPA's IND Approval for P-Ib MATCH Study of ATG-008 (onatasertib) ATG-010 (selinexor) to Treat Diffuse Large B-Cell Lymphoma

Antengene's Receives NMPA's IND Approval for P-Ib MATCH Study of ATG-008 (onatasertib) ATG-010 (selinexor) to Treat Diffuse Large...

  • November 2, 2021
Genentech Reports Results of Polivy (polatuzumab vedotin-piiq) + R-CHP in P-III POLARIX Trial for the Treatment of Diffuse Large B-Cell Lymphoma

Genentech Reports Results of Polivy (polatuzumab vedotin-piiq) + R-CHP in P-III POLARIX Trial for the Treatment of Diffuse Large B...

  • August 9, 2021
Celltrion Presents Real-World Data of Truxima (biosimilar- rituximab) for Diffuse Large B-Cell Lymphoma at EHA 2021

Celltrion Presents Real-World Data of Truxima (biosimilar- rituximab) for Diffuse Large B-Cell Lymphoma at EHA 2021

  • June 14, 2021
Incyte and MorphoSys Report First Patient Dosing in P-III frontMIND Study of Tafasitamab + Lenalidomide as a 1L Treatment for DLBCL

Incyte and MorphoSys Report First Patient Dosing in P-III frontMIND Study of Tafasitamab + Lenalidomide as a 1L Treatment for DLBC...

  • May 12, 2021
ADC Therapeutics' Zynlonta (loncastuximab tesirine-lpyl) Receives the US FDA's Approval for the Treatment of R/R Diffuse Large B-Cell Lymphoma

ADC Therapeutics' Zynlonta (loncastuximab tesirine-lpyl) Receives the US FDA's Approval for the Treatment of R/R Diffuse Large B-C...

  • April 23, 2021
Chugai's Polivy Receives MHLW's Approval for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Chugai's Polivy Receives MHLW's Approval for Relapsed or Refractory Diffuse Large B-cell Lymphoma

  • March 25, 2021
Roche Highlights Data from the P-III (STARGLO) Trial of Columvi to Treat Diffuse Large B-Cell Lymphoma at EHA 2024

    Roche Highlights Data from the P-III (STARGLO) Trial of Columvi to Treat Diffuse Large B-Cell Lymphoma at EHA 2024

    • June 17, 2024
    Pfizer Reports the P-III (ECHELON-3) Trial Results of Adcetris for Treating R/R Diffuse Large B-cell Lymphoma (DLBCL)

      Pfizer Reports the P-III (ECHELON-3) Trial Results of Adcetris for Treating R/R Diffuse Large B-cell Lymphoma (DLBCL)

      • June 3, 2024
      Roche Reports Data from the P-III Clinical Evaluation of Columvi to Treat R/R Diffuse Large B-cell Lymphoma

        Roche Reports Data from the P-III Clinical Evaluation of Columvi to Treat R/R Diffuse Large B-cell Lymphoma

        • April 15, 2024
        Pfizer Reports P-III Study Results of Adcetris for Treating Diffuse Large B-cell Lymphoma (DLBCL)

          Pfizer Reports P-III Study Results of Adcetris for Treating Diffuse Large B-cell Lymphoma (DLBCL)

          • March 13, 2024
          Shanghai Henlius Biotech Reports the Results of HLX01 (biosimilar, rituximab) in P-III Trial for the Treatment of Diffuse Large B-Cell Lymphoma

            Shanghai Henlius Biotech Reports the Results of HLX01 (biosimilar, rituximab) in P-III Trial for the Treatment of Diffuse Large B-...

            • February 6, 2024
            Roche’s Glofitamab Receives NICE Recommendation for the Treatment of Diffuse Large B-Cell Lymphoma

              Roche’s Glofitamab Receives NICE Recommendation for the Treatment of Diffuse Large B-Cell Lymphoma

              • October 19, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.